# Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)

> **NCT06832917** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Wan He** · enrollment: 238 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** AK104 plus
- **DRUG:** Chemo only

## Key facts

- **NCT ID:** NCT06832917
- **Lead sponsor:** Wan He
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832917, "Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06832917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*